Application 215358

Type: NDA
Sponsor: NOVARTIS PHARMS CORP

Application Products#

Product, Drug, Ingredient table
Product	Drug	Ingredient	Form	Strength	Reference drug	Reference standard
001	SCEMBLIX	ASCIMINIB	TABLET;ORAL	20MG	No	No
002	SCEMBLIX	ASCIMINIB	TABLET;ORAL	40MG	No	No
003	SCEMBLIX	ASCIMINIB HYDROCHLORIDE	TABLET;ORAL	EQ 100MG BASE	Yes	Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	RLD / RS	Approval date
N215358-001	SCEMBLIX	ASCIMINIB HYDROCHLORIDE	EQ 20MG BASE	TABLET / ORAL	RLD	2021-10-29
N215358-002	SCEMBLIX	ASCIMINIB HYDROCHLORIDE	EQ 40MG BASE	TABLET / ORAL	RLD	2021-10-29
N215358-003	SCEMBLIX	ASCIMINIB HYDROCHLORIDE	EQ 100MG BASE	TABLET / ORAL	RLD, RS	2024-04-18

Orange Book patents#

Current patent rows page 1 of 1 · 12 matching rows.

Application-product, Patent, Expiration table
Application-product	Patent	Expiration	Use code	Coverage / status	Submission date
N215358-001	8829195	2035-10-29	U-1374	Drug substance	2021-11-19
N215358-001	11407735	2040-05-14		Drug substance	2022-08-23
N215358-001	12252478	2040-05-14		Drug product	2025-04-04
N215358-001	12252479	2040-05-17	U-1374		2025-04-04
N215358-002	8829195	2035-10-29	U-1374	Drug substance	2021-11-19
N215358-002	11407735	2040-05-14		Drug substance	2022-08-23
N215358-002	12252478	2040-05-14		Drug product	2025-04-04
N215358-002	12252479	2040-05-17	U-1374		2025-04-04
N215358-003	8829195	2035-10-29	U-1374	Drug substance	2024-05-10
N215358-003	11407735	2040-05-14		Drug substance	2024-05-10
N215358-003	12252478	2040-05-14		Drug product	2025-04-04
N215358-003	12252479	2040-05-17	U-1374		2025-04-04

Orange Book exclusivity#

Current exclusivity rows page 1 of 1 · 19 matching rows.

Application-product, Exclusivity code, Expiration table
Application-product	Exclusivity code	Expiration
N215358-001	NCE	2026-10-29
N215358-001	I-953	2027-10-29
N215358-001	I-954	2027-10-29
N215358-001	M-318	2028-10-02
N215358-001	ODE-381	2028-10-29
N215358-001	ODE-382	2028-10-29
N215358-001	ODE-499	2031-10-29
N215358-001	ODE-500	2031-10-29
N215358-002	NCE	2026-10-29
N215358-002	I-953	2027-10-29
N215358-002	I-954	2027-10-29
N215358-002	M-318	2028-10-02
N215358-002	ODE-381	2028-10-29
N215358-002	ODE-382	2028-10-29
N215358-002	ODE-499	2031-10-29
N215358-002	ODE-500	2031-10-29
N215358-003	NCE	2026-10-29
N215358-003	M-318	2028-10-02
N215358-003	ODE*	2028-10-29

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 90 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	RLD / RS	Approval date	Source SHA-256
2026-10-15 13:18:30	2026-09	N215358-001	SCEMBLIX	EQ 20MG BASE	TABLET / ORAL	RLD	2021-10-29	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N215358-002	SCEMBLIX	EQ 40MG BASE	TABLET / ORAL	RLD	2021-10-29	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N215358-003	SCEMBLIX	EQ 100MG BASE	TABLET / ORAL	RLD, RS	2024-04-18	`c2088c7a36db…`
2026-09-14 22:38:34	2026-08	N215358-001	SCEMBLIX	EQ 20MG BASE	TABLET / ORAL	RLD	2021-10-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N215358-002	SCEMBLIX	EQ 40MG BASE	TABLET / ORAL	RLD	2021-10-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N215358-003	SCEMBLIX	EQ 100MG BASE	TABLET / ORAL	RLD, RS	2024-04-18	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N215358-001	SCEMBLIX	EQ 20MG BASE	TABLET / ORAL	RLD	2021-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-002	SCEMBLIX	EQ 40MG BASE	TABLET / ORAL	RLD	2021-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-003	SCEMBLIX	EQ 100MG BASE	TABLET / ORAL	RLD, RS	2024-04-18	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N215358-001	SCEMBLIX	EQ 20MG BASE	TABLET / ORAL	RLD	2021-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-002	SCEMBLIX	EQ 40MG BASE	TABLET / ORAL	RLD	2021-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-003	SCEMBLIX	EQ 100MG BASE	TABLET / ORAL	RLD, RS	2024-04-18	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N215358-001	SCEMBLIX	EQ 20MG BASE	TABLET / ORAL	RLD	2021-10-29	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N215358-002	SCEMBLIX	EQ 40MG BASE	TABLET / ORAL	RLD, RS	2021-10-29	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N215358-003	SCEMBLIX	EQ 100MG BASE	TABLET / ORAL	RLD	2024-04-18	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N215358-001	SCEMBLIX	EQ 20MG BASE	TABLET / ORAL	RLD	2021-10-29	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N215358-002	SCEMBLIX	EQ 40MG BASE	TABLET / ORAL	RLD, RS	2021-10-29	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N215358-003	SCEMBLIX	EQ 100MG BASE	TABLET / ORAL	RLD	2024-04-18	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N215358-001	SCEMBLIX	EQ 20MG BASE	TABLET / ORAL	RLD	2021-10-29	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N215358-002	SCEMBLIX	EQ 40MG BASE	TABLET / ORAL	RLD, RS	2021-10-29	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N215358-003	SCEMBLIX	EQ 100MG BASE	TABLET / ORAL	RLD	2024-04-18	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N215358-001	SCEMBLIX	EQ 20MG BASE	TABLET / ORAL	RLD	2021-10-29	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N215358-002	SCEMBLIX	EQ 40MG BASE	TABLET / ORAL	RLD, RS	2021-10-29	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N215358-003	SCEMBLIX	EQ 100MG BASE	TABLET / ORAL	RLD	2024-04-18	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N215358-001	SCEMBLIX	EQ 20MG BASE	TABLET / ORAL	RLD	2021-10-29	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N215358-002	SCEMBLIX	EQ 40MG BASE	TABLET / ORAL	RLD, RS	2021-10-29	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N215358-003	SCEMBLIX	EQ 100MG BASE	TABLET / ORAL	RLD	2024-04-18	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N215358-001	SCEMBLIX	EQ 20MG BASE	TABLET / ORAL	RLD	2021-10-29	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N215358-002	SCEMBLIX	EQ 40MG BASE	TABLET / ORAL	RLD, RS	2021-10-29	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N215358-003	SCEMBLIX	EQ 100MG BASE	TABLET / ORAL	RLD	2024-04-18	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N215358-001	SCEMBLIX	EQ 20MG BASE	TABLET / ORAL	RLD	2021-10-29	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N215358-002	SCEMBLIX	EQ 40MG BASE	TABLET / ORAL	RLD, RS	2021-10-29	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N215358-003	SCEMBLIX	EQ 100MG BASE	TABLET / ORAL	RLD	2024-04-18	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N215358-001	SCEMBLIX	EQ 20MG BASE	TABLET / ORAL	RLD	2021-10-29	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N215358-002	SCEMBLIX	EQ 40MG BASE	TABLET / ORAL	RLD, RS	2021-10-29	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N215358-003	SCEMBLIX	EQ 100MG BASE	TABLET / ORAL	RLD	2024-04-18	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N215358-001	SCEMBLIX	EQ 20MG BASE	TABLET / ORAL	RLD	2021-10-29	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N215358-002	SCEMBLIX	EQ 40MG BASE	TABLET / ORAL	RLD, RS	2021-10-29	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N215358-003	SCEMBLIX	EQ 100MG BASE	TABLET / ORAL	RLD	2024-04-18	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N215358-001	SCEMBLIX	EQ 20MG BASE	TABLET / ORAL	RLD	2021-10-29	`79d66fd596c7…`

Observed Orange Book patent history#

Patent history page 1 of 6 · 208 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Patent	Expiration	Use code	Coverage / status	Submission date	Source SHA-256
2026-10-15 13:18:30	2026-09	N215358-001	8829195	2035-10-29	U-1374	Drug substance	2021-11-19	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N215358-001	11407735	2040-05-14		Drug substance	2022-08-23	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N215358-001	12252478	2040-05-14		Drug product	2025-04-04	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N215358-001	12252479	2040-05-17	U-1374		2025-04-04	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N215358-002	8829195	2035-10-29	U-1374	Drug substance	2021-11-19	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N215358-002	11407735	2040-05-14		Drug substance	2022-08-23	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N215358-002	12252478	2040-05-14		Drug product	2025-04-04	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N215358-002	12252479	2040-05-17	U-1374		2025-04-04	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N215358-003	8829195	2035-10-29	U-1374	Drug substance	2024-05-10	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N215358-003	11407735	2040-05-14		Drug substance	2024-05-10	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N215358-003	12252478	2040-05-14		Drug product	2025-04-04	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N215358-003	12252479	2040-05-17	U-1374		2025-04-04	`c2088c7a36db…`
2026-09-14 22:38:34	2026-08	N215358-001	8829195	2035-10-29	U-1374	Drug substance	2021-11-19	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N215358-001	11407735	2040-05-14		Drug substance	2022-08-23	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N215358-001	12252478	2040-05-14		Drug product	2025-04-04	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N215358-001	12252479	2040-05-17	U-1374		2025-04-04	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N215358-002	8829195	2035-10-29	U-1374	Drug substance	2021-11-19	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N215358-002	11407735	2040-05-14		Drug substance	2022-08-23	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N215358-002	12252478	2040-05-14		Drug product	2025-04-04	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N215358-002	12252479	2040-05-17	U-1374		2025-04-04	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N215358-003	8829195	2035-10-29	U-1374	Drug substance	2024-05-10	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N215358-003	11407735	2040-05-14		Drug substance	2024-05-10	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N215358-003	12252478	2040-05-14		Drug product	2025-04-04	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N215358-003	12252479	2040-05-17	U-1374		2025-04-04	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N215358-001	8829195	2035-10-29	U-1374	Drug substance	2021-11-19	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-001	11407735	2040-05-14		Drug substance	2022-08-23	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-001	12252478	2040-05-14		Drug product	2025-04-04	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-001	12252479	2040-05-17	U-1374		2025-04-04	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-002	8829195	2035-10-29	U-1374	Drug substance	2021-11-19	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-002	11407735	2040-05-14		Drug substance	2022-08-23	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-002	12252478	2040-05-14		Drug product	2025-04-04	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-002	12252479	2040-05-17	U-1374		2025-04-04	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-003	8829195	2035-10-29	U-1374	Drug substance	2024-05-10	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-003	11407735	2040-05-14		Drug substance	2024-05-10	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-003	12252478	2040-05-14		Drug product	2025-04-04	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-003	12252479	2040-05-17	U-1374		2025-04-04	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N215358-001	8829195	2035-10-29	U-1374	Drug substance	2021-11-19	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-001	11407735	2040-05-14		Drug substance	2022-08-23	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-001	12252478	2040-05-14		Drug product	2025-04-04	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-001	12252479	2040-05-17	U-1374		2025-04-04	`011fe1cb6892…`

Observed Orange Book exclusivity history#

Exclusivity history page 2 of 9 · 351 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Exclusivity code	Expiration	Source SHA-256
2026-08-18 06:07:40	2026-07	N215358-001	I-954	2027-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-001	M-318	2028-10-02	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-001	ODE-381	2028-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-001	ODE-382	2028-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-001	ODE-499	2031-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-001	ODE-500	2031-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-002	NCE	2026-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-002	I-953	2027-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-002	I-954	2027-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-002	M-318	2028-10-02	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-002	ODE-381	2028-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-002	ODE-382	2028-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-002	ODE-499	2031-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-002	ODE-500	2031-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-003	NCE	2026-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-003	M-318	2028-10-02	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N215358-003	ODE*	2028-10-29	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N215358-001	NCE	2026-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-001	I-953	2027-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-001	I-954	2027-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-001	M-318	2028-10-02	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-001	ODE-381	2028-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-001	ODE-382	2028-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-001	ODE-499	2031-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-001	ODE-500	2031-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-002	NCE	2026-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-002	I-953	2027-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-002	I-954	2027-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-002	M-318	2028-10-02	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-002	ODE-381	2028-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-002	ODE-382	2028-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-002	ODE-499	2031-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-002	ODE-500	2031-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-003	NCE	2026-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-003	M-318	2028-10-02	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N215358-003	ODE*	2028-10-29	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N215358-001	NCE	2026-10-29	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N215358-001	I-953	2027-10-29	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N215358-001	I-954	2027-10-29	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N215358-001	ODE-381	2028-10-29	`31067a03dcf5…`

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 6 matching rows.

NDC, Name, Nonproprietary name table
NDC	Name	Nonproprietary name	Labeler	Marketing category	Status
0078-1091	SCEMBLIX	asciminib	Novartis Pharmaceuticals Corporation	NDA	Current
0078-1091	SCEMBLIX	asciminib	Novartis Pharmaceuticals Corporation	NDA	Current
0078-1091	SCEMBLIX	asciminib	Novartis Pharmaceuticals Corporation	NDA	Current
0078-1098	SCEMBLIX	asciminib	Novartis Pharmaceuticals Corporation	NDA	Current
0078-1098	SCEMBLIX	asciminib	Novartis Pharmaceuticals Corporation	NDA	Current
0078-1098	SCEMBLIX	asciminib	Novartis Pharmaceuticals Corporation	NDA	Current

Documents#

Document, Submission type, Date table
Document	Submission type	Date
84339	SUPPL	2025-11-28
84328	SUPPL	2025-11-28
84327	SUPPL	2025-11-28
83656	SUPPL	2025-10-03
83648	SUPPL	2025-10-03
81022	SUPPL	2025-02-05
80053	SUPPL	2024-10-30
80052	SUPPL	2024-10-30
80890	SUPPL	2024-10-29
80040	SUPPL	2024-10-29
79349	SUPPL	2024-08-09
79343	SUPPL	2024-08-08
76550	SUPPL	2023-11-13
76543	SUPPL	2023-11-09
74639	SUPPL	2023-06-27
74629	SUPPL	2023-06-27
72321	SUPPL	2022-10-13
72318	SUPPL	2022-10-13
69414	ORIG	2021-11-24
69413	ORIG	2021-11-24
69178	ORIG	2021-11-01
69177	ORIG	2021-11-01
69163	ORIG	2021-10-29
69162	ORIG	2021-10-29